MR-guided radiation therapy for prostate cancer

Reduce margins. Reduce fractions. Preserve function.

Continuous MR imaging reveals just how much the prostate moves and changes shape between and during fractions. This mobility challenges treatment accuracy and precision. While margins account for uncertainties, irradiation of healthy tissue can result in toxicity and associated side effects.

Elekta Unity MR guided radiation therapy allows you to see the prostate and surrounding organs clearly as you treat, enabling you to respond to change and motion, and to adapt the plan for each patient and every fraction. With Elekta Unity you can:

Reduce margins with certainty. Reduce number of fractions to 5. Preserve quality of life and erectile function.

Clinical benefits

Elekta Unity MR-guided radiation therapy for prostate cancer

Elekta Unity allows clinicians to treat even the most challenging prostate SBRT cases with low toxicity.

Use smaller margins to spare OARs and reduce toxicity
Complete prostate SBRT in 5 fractions or less
Increase efficiency with fiducial/spacer-free treatments
Enhance patient comfort with shorter courses and fewer side effects
Personalize treatments with advanced imaging capabilities

Clinician preparing patient for treatment on Elekta Unity

See the difference for prostate cancer treatments

Prostate SBRT in just 2 fractions

Elekta Unity leads the way to ultra-hypofractionation. Where five fraction SBRT is standard on Unity, preliminary findings from the HERMES trial highlight that low levels of acute toxicity are also achieved with two-fraction MR-guided adaptive SBRT in men with intermediate or lower high-risk prostate cancer.

Safeguard erectile function

Elekta Unity prioritizes the preservation of erectile function with exquisite soft tissue visualization and online adaptation to spare the neurovascular bundle and internal pudendal arteries.

Account for intrafraction drift

Elekta Unity addresses intrafraction drift by providing real-time visualization of the prostate during treatment. Detection and rapid correction of significant drift, caused by e.g. bladder filling or patient relaxation, leads to reduced toxicity and improved efficiency.

Escalate dose to tumor

Superior sub-structural image quality with Elekta Unity allows the tumor to be clearly visualized, providing the possibility of dose escalation to tumor cells within the prostate rather than treating the entire organ.

Image courtesy of Odense University Hospital

Clinical evidence

Learn more how Unity is benefiting prostate cancer patients

Clinical trials

Articles

Webinars

Bibliographies

Case studies

MIRAGE clinical trial

The MIRAGE phase 3 randomized clinical trial demonstrated that MR-guided SBRT resulted in significantly reduced grade 2+ gastrointestinal and genitourinary toxicity compared to CT-guided SBRT for localized prostate cancer treatment.

Clinical trial

MOMENTUM study

The ongoing MOMENTUM study highlights the reduced toxicity that can be achieved for prostate cancer patients treated using MR-guided radiation therapy with Elekta Unity.

Clinical trial

HERMES trial

Interim results from the HERMES randomized trial show that two-fraction MR-guided adaptive SBRT with Elekta Unity has low levels of acute toxicity in men with intermediate or lower high-risk prostate cancer.

Clinical trial

ERECT trial

The ERECT trial aims to show preserved erectile function in prostate cancer patients treated with nerve- and vascular-sparing MR-guided radiation therapy.

Clinical trial